New and experimental hepatitis C treatment: latest news

New and experimental hepatitis C treatment resources

New and experimental hepatitis C treatment features

New and experimental hepatitis C treatment news from aidsmap

More news

New and experimental hepatitis C treatment news selected from other sources

  • Achillion partners with J&J to develop hepatitis C drugs

    Achillion Pharmaceuticals Inc said it will collaborate with Johnson & Johnson to develop and market its hepatitis C drugs including an oral regimen that could work on all genotypes and shorten treatment time.

    20 May 2015 | Reuters
  • ViiV Healthcare Begins Phase III Programme with dolutegravir/rilpivirine Combination for HIV Maintenance Therapy

    The Phase III programme will evaluate the efficacy, safety, and tolerability of switching to dolutegravir plus rilpivirine from current INI-,NNRTI-, or PI-based antiretroviral regimen in HIV-1-infected adults who are virologically suppressed. In the clinical trials, dolutegravir and rilpivirine will be provided as individual tablets; development of the single-tablet formulation will be concurrent with conduct of the trials.

    06 May 2015 | Viiv Healthcare press release
  • Merck Faces Hep C Pricing Dilemma to Counter Gilead, Abbvie

    Merck has previously stated that it will seek approval for the grazoprevir/elbasvir combination pill in the middle of the year. If approved by the end of the year or in early 2016 -- and there's probably little risk the therapy won't be approved -- Merck's dilemma will be finding a way to grab market share for a new hepatitis C therapy without any clinical or convenience advantages over the existing competition.

    09 April 2015 | The Street
  • Grazoprevir/Elbasvir, Merck’s Investigational Chronic Hepatitis C Therapy, Granted FDA Breakthrough Therapy Designations

    Merck today announced that grazoprevir/elbasvir, an investigational single tablet regimen for the treatment of chronic hepatitis C virus (HCV) infection, has received two new Breakthrough Therapy designations from the U.S. Food and Drug Administration (FDA) for the treatment of patients with chronic HCV genotype 4 (GT4) infection, and for the treatment of chronic HCV genotype 1 (GT1) infection in patients with end stage renal disease on hemodialysis.

    09 April 2015 | Merck press release
  • At 50 Cents a Pill, Allergy Drug Could Best $1000 Sovaldi, Harvoni

    Published today in the journal Science Translational Medicine, researchers from the National Institutes of Health (NIH) reported chlorcyclizine prevented hepatitis C infection in a petri dish and in humanized mice. They said it was effective and did and did not produce any significant cell toxicity when given along with existing drugs to treat hepatitis C.

    09 April 2015 | Healthline
  • FDA to review re-submitted Bristol-Myers hepatitis C drug

    U.S. regulators have accepted Bristol-Myers Squibb Co's re-submitted marketing application for an experimental hepatitis C treatment after the drugmaker was forced last year to withdraw its initial request.

    12 March 2015 | Reuters
  • New hepatitis C treatments highly effective for HIV/HCV coinfected people

    A pair of interferon-free combinations -- AbbVie's 3-drug Viekira Pak regimen and Gilead Science's sofosbuvir/ledipasvir (Harvoni) -- demonstrated good safety and cured more than 90% of genotype 1 HIV/HCV coinfected people, according to studies published in the February 23 advance edition of the Journal of the American Medical Association.

    26 February 2015 | HIVandHepatitis.com
  • Health News Review analysis of Reuters' coverage of new hepatitis C drugs

    We wish that more stories would bring some skeptical thinking to their coverage of expensive new hepatitis C treatments. The emphasis on short-term effects obscures the lack of long-term data about benefits.

    13 February 2015 | Health News Review
  • UNITAID: 2015 Hepatitis C medicines technology and market landscape

    This report takes stock of a rapidly changing market, where new products have the potential to become “blockbusters” almost overnight – but also risk becoming quickly outdated due to superior products entering the market.

    13 February 2015 | UNITAID
  • FDA revokes breakthrough status for BMS hep C drug

    The big biotech tells FierceBiotech in a statement that the agency has "informed Bristol-Myers Squibb that, due to the evolving HCV treatment landscape, the agency intends to rescind the breakthrough therapy designation for certain genotype 1 hepatitis C regimens related to daclatasvir." Bristol-Myers then went on to add that the decision will not impact its timetable on an NDA for daclatasvir, which faces a unique set of challenges all its own.

    11 February 2015 | Fierce Biotech
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.